Marchex Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0300 |
| EPS Surprise | -200.00% |
| Revenue estimate | 10.889M |
| Revenue actual | 10.618M |
| Revenue Surprise | -2.49% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0400 |
| EPS Surprise | -300.00% |
| Revenue estimate | 11M |
| Revenue actual | 10.848M |
| Revenue Surprise | -1.38% |
| Release date | Nov 13, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0200 |
| EPS Surprise | -300.00% |
| Revenue estimate | 10.969M |
| Revenue actual | 11.514M |
| Revenue Surprise | 4.97% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS Surprise | 300.00% |
| Revenue estimate | 12.93M |
| Revenue actual | 11.655M |
| Revenue Surprise | -9.86% |
Last 4 Quarters for Marchex
Below you can see how MCHX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $2.03 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS surprise | 300.00% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $2.11 |
| Aug 07, 2025 | $2.12 |
| Aug 08, 2025 | $2.13 |
| Aug 11, 2025 | $1.97 |
| Aug 12, 2025 | $2.03 |
| Aug 13, 2025 | $1.81 |
| Aug 14, 2025 | $1.81 |
| Aug 15, 2025 | $1.94 |
| Aug 18, 2025 | $1.98 |
| 4 days before | -3.79% |
| 4 days after | -2.46% |
| On release day | -10.84% |
| Change in period | -6.16% |
| Release date | Nov 13, 2025 |
| Price on release | $1.54 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0200 |
| EPS surprise | -300.00% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $1.67 |
| Nov 10, 2025 | $1.65 |
| Nov 11, 2025 | $1.64 |
| Nov 12, 2025 | $1.60 |
| Nov 13, 2025 | $1.54 |
| Nov 14, 2025 | $1.58 |
| Nov 17, 2025 | $1.45 |
| Nov 18, 2025 | $1.45 |
| Nov 19, 2025 | $1.45 |
| 4 days before | -7.78% |
| 4 days after | -5.71% |
| On release day | 2.60% |
| Change in period | -13.05% |
| Release date | Mar 25, 2026 |
| Price on release | $1.49 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0400 |
| EPS surprise | -300.00% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $1.43 |
| Mar 20, 2026 | $1.34 |
| Mar 23, 2026 | $1.41 |
| Mar 24, 2026 | $1.43 |
| Mar 25, 2026 | $1.49 |
| Mar 26, 2026 | $1.42 |
| Mar 27, 2026 | $1.54 |
| Mar 30, 2026 | $1.56 |
| Mar 31, 2026 | $1.55 |
| 4 days before | 4.20% |
| 4 days after | 4.03% |
| On release day | -4.70% |
| Change in period | 8.39% |
| Release date | May 13, 2026 |
| Price on release | $1.60 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0300 |
| EPS surprise | -200.00% |
| Date | Price |
|---|---|
| May 07, 2026 | $1.60 |
| May 08, 2026 | $1.58 |
| May 11, 2026 | $1.60 |
| May 12, 2026 | $1.59 |
| May 13, 2026 | $1.60 |
| May 14, 2026 | $1.62 |
| May 15, 2026 | $1.62 |
| May 18, 2026 | $1.66 |
| May 19, 2026 | $1.66 |
| 4 days before | 0% |
| 4 days after | 3.75% |
| On release day | 1.25% |
| Change in period | 3.75% |
Marchex Earnings Call Transcript Summary of Q1 2026
Marchex reported Q1 2026 revenue of $10.6M, roughly flat sequentially, and described an operational inflection driven by AI-enabled product evolution and deeper penetration of its top customers. Management is focused on selling bundled AI solutions that combine insights, automated actions and verifiable outcomes — an approach reinforced by early customer adoption from outreach to roughly one-third of the top 100 customers with about half of those purchasing recurring products or pilots. Marchex announced a definitive agreement to acquire Archenia (expected to close in July 2026 subject to shareholder approval), positioning the combined company to expand outcome-based solutions, cross-sell to existing enterprise customers, and materially increase addressable market. Financially, Marchex expects sequential revenue increases in Q2 and Q3 2026, with Q2 adjusted EBITDA now guided to $1.6M–$1.8M (up from >$1M prior guidance) and Q3 standalone adjusted EBITDA potentially around $2M (rising to ~$2.5M or more if Archenia closes), implying an annualized run-rate near $60M and potential 2026 run-rate growth of ~15%–20%. Management highlighted cost efficiencies from prior realignments and platform migrations, a lower recurring cost structure, and a path toward adjusted EBITDA margins of 10%+ and a Rule of 30–40 trajectory if projected growth and margin improvements are achieved. Cash was $9M at quarter end, down from $9.9M primarily due to payroll/severance; a $3M share buyback program remains authorized. Key investor takeaways: accelerating AI-driven product monetization, meaningful near-term EBITDA upside, potential material uplift and strategic scale from the Archenia acquisition, and management’s focus on selling high-value bundled solutions into a concentrated, high-revenue customer base.
Sign In
Buy MCHX